.jpg)
Highlights
- ADQ to acquire Acino, a Swiss-based pharmaceutical manufacturer with presence in more than 90 countries
- Investment builds on ADQ’s intent to develop an integrated pharma platform including advanced drug development, in-licensing, manufacturing, and commercialisation capabilities in select growth-leading markets
- Acino will be ADQ’s largest acquisition in its healthcare and pharma portfolio to date
ADQ, one of the region’s largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi’s diversified economy, has entered into a definitive agreement to acquire Swiss-based Acino, a leading provider of high-quality pharmaceuticals focused on growth-leading markets across the Middle East, Africa, Latin America, Russia, Ukraine and the CIS Region.
Acino is a leader in more than 20 therapeutic areas including gastroenterology, cardiovascular and pain relief for high-quality pharmaceutical products in novel drug delivery forms. With its own sales force and distribution partnerships, Acino is active in more than 90 countries. As a trusted partner to pharmaceutical companies worldwide, Acino also supplies bespoke one-stop solutions through contract manufacturing and out-licensing.
Building ADQ’s Integrated Pharma Platform
With the Acino acquisition, ADQ intends to create an integrated pharma platform in select growth-leading markets with formulation development, in-licensing, manufacturing, and commercialisation capabilities. Earlier this year, ADQ acquired Amoun Pharmaceutical Company, one of Egypt’s leading manufacturers, distributors and exporters of branded pharmaceutical and animal health products, and Pharmax Pharmaceuticals, a UAE-based pharmaceutical company which manufactures and markets affordable, branded generic medications. Additionally, ADQ purchased a minority stake in India-based Biocon Biologics Limited, which specialises in developing, manufacturing and marketing high-quality, affordable biosimilars across global markets.
Acino’s strong management, commercialisation capabilities, diverse product portfolio and licenses across many emerging markets will be essential to ADQ’s long-term strategy of developing its integrated pharma platform and meeting the need for high-quality, affordable medicines in the UAE and the broader region. The agreement builds on a collaboration agreement between Acino and Pharmax to license, manufacture, and supply select Acino products across the Middle East and Africa, based on the local needs of patients.
The definitive agreement is for ADQ to acquire 100 per cent of Acino from its current shareholders, which include Nordic Capital and Avista Capital Partners. The transaction is subject to customary closing conditions, including regulatory approvals.
About ADQ
Established in 2018, ADQ is an active global sovereign investor with a focus on critical infrastructure and supply chains. As a strategic partner to the Government of Abu Dhabi, ADQ invests in the growth of business platforms anchored in the Emirate that deliver value to local communities and long-term financial returns to its shareholder. ADQ’s expanding portfolio has a total book value of USD 225 billion (as at 30 June 2024) and encompasses companies across numerous core sectors of the economy, including energy and utilities, transport and logistics, food and agriculture, and healthcare and life sciences.
For more information, visit adq.ae or write to media@adq.ae. You can also follow ADQ on Instagram, LinkedIn, and X.
Direct to your inbox
ADQ News and Insights delivered directly to your inbox
